Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report 2017 - Novel Treatments Offer a Ray of Hope - Research and Markets
DUBLIN, April 26, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research.
The report profiles 34 companies including many key and niche players such as:
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (USA)
- Cardiorentis AG (Switzerland)
- CVie Therapeutics Limited (Taiwan)
- Cytokinetics, Inc. (USA)
- Merck & Co. (USA)
- Novartis AG (Switzerland)
- Orion Corporation (Finland)
- PhaseBio Pharmaceuticals, Inc. (USA)
Key Topics Covered:
1. INDUSTRY OVERVIEW
- Market Outlook
- Acute Heart Failure - An Overview of the Disease and Available Therapeutics
- Diuretics and Vasodilators - The First Line Therapy for AHF
- Select Key Diuretics for AHF Treatment by Dosage and Route of Administration
- Comparison of Most Common Vasodilators Used in ADHF Treatment
- Other Known Drugs for AHF - Lower Efficacy Thwarts Use
- Comparison of Select Inotropic Therapies for Acute Heart Failure Treatment
- Standard Approved AHF Therapeutics as per Agency Guidelines
2. MARKET DRIVERS, TRENDS & ISSUES
- Conventional Therapies Leave Considerable Unmet Needs
- Novel Treatments Offer a Ray of Hope
- Key AHF Therapeutics in the Pipeline
- Serelaxin Nears Trial Readout form RELAX-AHF-2
- Ularitide - A Novel Drug in Development for AHF
- Ularitide's Fate Hangs in Balance
- Impact of Ularitide's Clinical Trial Outcomes
- The Litany of Drug Failures Expands, Emphasis on Prevention Grows
- Failure of TRV027 - A Disappointment
- Other Promising Drugs under Development
- CAP-1002 (Capricor Therapeutics, Inc.)
- Istaroxime (CVie Therapeutics)
- PB-1046 (PhaseBio Pharmaceuticals)
- omecamtiv mecarbil (Cytokinetics & Amgen)
- CXL-1427 (Bristol Myers Squibb)
- Research Findings
- Kidney Dysfunction - Predictor of Acute Heart failure
- Genetic Influence on Heart Disease among African Americans
- Higher Body Mass Index - A Key Risk Factor for AHF
- Supplemental Oxygen Therapy May not be for All Cases of AHF
- Macro Growth Drivers
- Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics
3. TREATMENT OF ACUTE HEART FAILURE (AHF)
- Acute Decompensated Heart Failure Treatment by Type and Action Mechanism
- A Review of Drug Classes
- ACE Inhibitors
- Aldosterone Antagonists
- Angiotensin II Receptor Blockers (ARBs)
- ß-Blockers
- Calcium Channel Blockers
- Cardiac Glycosides
- Diuretics
- Dosage of Diuretics Used in the Treatment of AHF
- Inotropic Agents
- Digoxin (Lanoxin)
- Morphine
- Vasodilators/Nitrates
- Vasodilators Used in AHF Treatment: Type, Indications for Use and Side Effects
- Drug Tolerance of Patients Based on Signs and Symptoms
- Treatment on the Basis of Adverse Signs
- Oliguria/Anuria (Cardiorenal Syndrome)
- Drowsiness/Confusion
- Hypotension (systolic BP<_0mmhg_ />
- Persistent Pulmonary Edema
- Lifestyle Changes
4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS
- Types of AHF
- Causes of AHF
- Coronary Heart Disease
- Cardiomyopathy
- High BP
- Damaged Heart Valves
- Patho-Physiology of AHF
- Signs and Symptoms
- Low Output
- Fluid Overload/Congestion
- Left-Sided Failure
- Right-Sided Failure
- Biventricular Failure
- Diagnosis
- Classification of AHF
- Left Side and Right Side
- Systolic Dysfunction and Diastolic Dysfunction
- Backward and Forward Failure
- Low-Output Heart Failure and High-Output Heart Failure
- Functional Classification
- By NYHA
- By American College of Cardiology/American Heart Association
- Phases of Evaluation and Management of AHF Patients
- Early/Initial Phase
- In-Hospital Phase
- Pre-Discharge Phase
- Early Post-Discharge Phase
5. RECENT INDUSTRY ACTIVITY
- Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic
- Renova Acquires Stresscopin from Janssen
- Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma
- CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime
- ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug
- Trevena's TRV027 Fails to Meet Clinical Study Endpoints
- NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras®
- Cardiorentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF
- FDA Grants Fast Track Designation to Cardiorentis' Ularitide
- Bristol-Myers Squibb Completes Acquisition of Cardioxyl
- Cardiorentis Completes Enrollment in Phase III Trial of Ularitide
- Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide
- Cardiorentis Enters into Collaboration with Roche
- Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic
- Cardiorentis Enters into 45 million Financing Agreement with HC Royalty
- USPTO Grants Patent to Trevena's TRV027
- FDA Declines Approval for Novartis' Serelaxin
6. FOCUS ON SELECT PLAYERS
7. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 34 (including Divisions/Subsidiaries - 35)
- The United States (18)
- Japan (2)
- Europe (10)
- Germany (2)
- The United Kingdom (2)
- Italy (1)
- Rest of Europe (5)
- Asia-Pacific (Excluding Japan) (5)
For more information about this report visit http://www.researchandmarkets.com/research/9nm929/acute_heart
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article